Page 20 - 《中国药房》2021年第9期

专利视角下我国医药中间体应用技术发展态势研究 Δ

方 曦 ，刘 跃，尤 宇（上海应用技术大学经济与管理学院，上海 200235）
＊

中图分类号 R-1；R319；R914.5 文献标志码 A 文章编号 1001-0408（2021）09-1038-07
DOI 10.6039/j.issn.1001-0408.2021.09.03

摘 要 目的：协助企业了解医药中间体行业相关的技术点和发展趋势，为医药中间体应用技术提供新的发展思路和技术支持。
方法：将医药中间体涉及的核心技术列为研究对象并分为四级，检索国家知识产权局专利检索系统（SIPO）及合享（INCOPAT）、智
慧芽（PatSnap）专利数据库中2020年2月2日之前公开/公告的医药中间体专利数据。运用专利分析方法分析医药中间体专利申
请趋势以及专利申请人，同时对医药中间体二、三级技术进行详细分析。最后运用SPSS 24.0软件对我国医药中间体专利的申请
数量进行曲线拟合预测分析。结果：共检索出相关专利12 103条；二级技术分类下，抗生素类药物中间体专利有331条，解热镇痛
药物中间体专利有474条，心血管药物中间体专利有1 227条，抗癌用医药中间体专利有1 550条。全球与我国医药中间体专利申
请数量均逐年递增，中国大陆的专利申请数量是最多的，其中江苏、上海、山东等省份专利申请数量排名前3位；排在前10位的专
利申请人中有8家为我国国内企业或高校，他们也在我国医药中间体专利申请人构成中排名前2位。医药中间体二级技术中，心
血管药物中间体专利申请数量占比最大（占32％），其次是抗癌用医药中间体技术（占30％）；三级技术中，医药中间体在产品（占
35％）、方法（占35％）和用途（占28％）上均有专利申请。我国医药中间体专利申请数量的曲线拟合显示，当前申请趋势与三次曲
线模型拟合程度最高，并预测我国2020、2021年的专利申请数量分别为688、781件。结论：医药中间体技术在我国发展迅速，高校
与企业都具备相当的研发实力；企业除了在技术创新上有所发展外，还可以考虑校企合作的发展思路以及企业间的专利交叉许
可，助力我国医药中间体产业更好发展。
关键词 医药中间体；专利；预测；曲线估计

Research on the Development Trend of Pharmaceutical Intermediates Application Technology in China
from the Perspective of Patent
FANG Xi，LIU Yue，YOU Yu（School of Economics and Management，Shanghai Institute of Technology，
Shanghai 200235，China）

ABSTRACT OBJECTIVE：To assist enterprises to understand the technical points and development trend of pharmaceutical
intermediates industry，and to provide new development ideas and technical support for pharmaceutical intermediates application
technology. METHODS：Taking the core technology involved in pharmaceutical intermediates as the research object and divided
into four levels，the patent data of pharmaceutical intermediates published（announced）before Feb. 2nd，2020 in State Intellectual
Property Office（SIPO），INCOPAT and PatSnap patent databases were searched. Patent analysis method was used to analyze the
patent application trend and patent applicants of pharmaceutical intermediates，and the secondary and tertiary technologies of
pharmaceutical intermediates were analyzed in detail. Finally，SPSS 24.0 software was used for curve fitting prediction analysis of
the number of patent applications for pharmaceutical intermediates in China. RESULTS：A total of 12 103 related patents were
retrieved. Under the secondary technology classification，there were 331 patents for antibiotic drug intermediates，474 patents for
antipyretic and analgesic drug intermediates，1 227 patents for cardiovascular drug intermediates，and 1 550 patents for anticancer
drug intermediates. The numbers of patent applications for pharmaceutical intermediates in the world and China were increasing
year by year，and Chinese mainland had the largest number of patent applications. The number of patent applications in Jiangsu，
Shanghai and Shandong ranked the top 3. Among the top 10 patent，8 were domestic enterprises or universities，and they also
ranked the top 2 in the composition of pharmaceutical intermediates applicants in China. Among the secondary technologies of
pharmaceutical intermediates，cardiovascular pharmaceutical intermediates accounted for the largest proportion of patent applications
（32％ ），followed by anticancer pharmaceutical intermediates （30％ ）. Among the tertiary technologies，there were patent
applications for the products（35％），methods（35％）and uses（28％）of pharmaceutical intermediates. The curve fitting of the
number of patent applications for pharmaceutical intermediates in China showed that the current trend of patent applications was the
best fitted with the cubic curve model，and it was predicted that the number of patent applications in 2020 and 2021 will be 688
and 781 respectively. CONCLUSIONS：The technology of pharmaceutical intermediates has developed rapidly in China，and
universities and enterprises have considerable R&D strength. In addition to expanding in technological innovation，enterprises can
Δ 基金项目：国家重点研发计划资助项目（No.2017YFB1401100） also consider the development idea of school-enterprise
＊副教授，硕士生导师，博士。研究方向：知识产权管理、技术创 cooperation and patent cross licensing among enterprises to
新管理。电话：021-64941028。E-mail：Fangxi@sit.edu.cn help the better development of China’s pharmaceutical

·1038 · China Pharmacy 2021 Vol. 32 No. 9 中国药房 2021年第32卷第9期